Cargando…

Practice change in the management of metastatic urothelial carcinoma after ASCO 2020

Metastatic urothelial carcinoma (mUC) is an incurable and aggressive disease. In the past decades there have been few effective treatment options that have impacted the prognosis of mUC patients. However, in the last few years, several drugs have emerged as new treatment choices that are changing th...

Descripción completa

Detalles Bibliográficos
Autores principales: Gajate, Pablo, Torres-Jiménez, Javier, Bueno-Bravo, Carolina, Couñago, Felipe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769717/
https://www.ncbi.nlm.nih.gov/pubmed/33437659
http://dx.doi.org/10.5306/wjco.v11.i12.976
_version_ 1783629387056283648
author Gajate, Pablo
Torres-Jiménez, Javier
Bueno-Bravo, Carolina
Couñago, Felipe
author_facet Gajate, Pablo
Torres-Jiménez, Javier
Bueno-Bravo, Carolina
Couñago, Felipe
author_sort Gajate, Pablo
collection PubMed
description Metastatic urothelial carcinoma (mUC) is an incurable and aggressive disease. In the past decades there have been few effective treatment options that have impacted the prognosis of mUC patients. However, in the last few years, several drugs have emerged as new treatment choices that are changing the therapeutic landscape of mUC. Immune checkpoint inhibitors (ICIs) and targeted agents are useful treatment strategies that have been incorporated into our clinical practice. Nevertheless, cisplatin-based chemotherapy is still the standard of care in the first-line of metastatic disease. The results of the JAVELIN Bladder 100 phase 3 trial were presented at ASCO 2020, this trial evaluated the role of avelumab, an ICI, as maintenance therapy in patients who had not progressed after first-line platinum-based chemotherapy. The trial met its primary endpoint demonstrating an overall survival benefit with avelumab maintenance. In addition, new drugs and combinations are being evaluated to improve the outcomes of second and subsequent lines. Fibroblast growth factor receptor (FGFR) inhibitors and immunotherapy combinations were some of the strategies presented at ASCO 2020 that have shown promising results. Finally, the development of predictive biomarkers that help us in the decision-making process will be one of the most important challenges in the next years.
format Online
Article
Text
id pubmed-7769717
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-77697172021-01-11 Practice change in the management of metastatic urothelial carcinoma after ASCO 2020 Gajate, Pablo Torres-Jiménez, Javier Bueno-Bravo, Carolina Couñago, Felipe World J Clin Oncol Editorial Metastatic urothelial carcinoma (mUC) is an incurable and aggressive disease. In the past decades there have been few effective treatment options that have impacted the prognosis of mUC patients. However, in the last few years, several drugs have emerged as new treatment choices that are changing the therapeutic landscape of mUC. Immune checkpoint inhibitors (ICIs) and targeted agents are useful treatment strategies that have been incorporated into our clinical practice. Nevertheless, cisplatin-based chemotherapy is still the standard of care in the first-line of metastatic disease. The results of the JAVELIN Bladder 100 phase 3 trial were presented at ASCO 2020, this trial evaluated the role of avelumab, an ICI, as maintenance therapy in patients who had not progressed after first-line platinum-based chemotherapy. The trial met its primary endpoint demonstrating an overall survival benefit with avelumab maintenance. In addition, new drugs and combinations are being evaluated to improve the outcomes of second and subsequent lines. Fibroblast growth factor receptor (FGFR) inhibitors and immunotherapy combinations were some of the strategies presented at ASCO 2020 that have shown promising results. Finally, the development of predictive biomarkers that help us in the decision-making process will be one of the most important challenges in the next years. Baishideng Publishing Group Inc 2020-12-24 2020-12-24 /pmc/articles/PMC7769717/ /pubmed/33437659 http://dx.doi.org/10.5306/wjco.v11.i12.976 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Editorial
Gajate, Pablo
Torres-Jiménez, Javier
Bueno-Bravo, Carolina
Couñago, Felipe
Practice change in the management of metastatic urothelial carcinoma after ASCO 2020
title Practice change in the management of metastatic urothelial carcinoma after ASCO 2020
title_full Practice change in the management of metastatic urothelial carcinoma after ASCO 2020
title_fullStr Practice change in the management of metastatic urothelial carcinoma after ASCO 2020
title_full_unstemmed Practice change in the management of metastatic urothelial carcinoma after ASCO 2020
title_short Practice change in the management of metastatic urothelial carcinoma after ASCO 2020
title_sort practice change in the management of metastatic urothelial carcinoma after asco 2020
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769717/
https://www.ncbi.nlm.nih.gov/pubmed/33437659
http://dx.doi.org/10.5306/wjco.v11.i12.976
work_keys_str_mv AT gajatepablo practicechangeinthemanagementofmetastaticurothelialcarcinomaafterasco2020
AT torresjimenezjavier practicechangeinthemanagementofmetastaticurothelialcarcinomaafterasco2020
AT buenobravocarolina practicechangeinthemanagementofmetastaticurothelialcarcinomaafterasco2020
AT counagofelipe practicechangeinthemanagementofmetastaticurothelialcarcinomaafterasco2020